Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas

NCT00453427 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Peripheral T-cell Lymphomas

Interventions

DRUG: Alemtuzumab (Campath-1H)

Sponsor

Ontario Clinical Oncology Group (OCOG)

Collaborators

[object Object]
[object Object]